For years, the industry underpriced rare disease, undervalued underserved patients, and treated Chinese biotech as a discount aisle. This week, on three separate fronts, the market is catching up.

This week the FDA moved to make gene therapy development faster and less redundant for sponsors working in rare disease; a French pharmaceutical group placed $1.55 billion on a muscle disorder with no approved treatment; and the data confirmed what deal desks already know — Chinese biotech assets are now priced to reflect what they are: a primary source of global pharmaceutical innovation, not a secondary one. Separately, each is a data point. Together, they mark a turn — in how this industry prices risk, values patients, and sources the next generation of innovation.

On June 2, the FDA issued draft guidance that will, when finalized, allow gene therapy sponsors to draw on existing platform knowledge — chemistry, manufacturing and controls data, nonclinical results, prior clinical findings — rather than regenerating it from scratch for each new submission. The guidance targets genome-editing products in human somatic cells, a category that includes some of the most consequential programs in development for patients with rare and life-threatening diseases who have no other options.

The policy logic is sound: redundant testing slows programs that patients cannot afford to wait for. For founders in gene therapy and rare disease platforms, this is the clearest regulatory tailwind in years — and it arrives at a moment when acting leadership at CBER is actively signaling intent to accelerate, not stall.

On June 1, a French pharmaceutical group quietly placed one of the largest bets in rare neuromuscular disease in recent memory. Servier announced it would acquire the muscular dystrophy business of Edgewise Therapeutics for up to $2.65 billion — $1.55 billion upfront, with $1.1 billion in milestones. The lead asset is sevasemten, a first-in-class oral fast skeletal myosin inhibitor in a pivotal cohort for Becker muscular dystrophy and Phase 2 for Duchenne. BMD has no approved treatment. DMD carries a median life expectancy of around 30 years. Both are X-linked disorders that progress irreversibly from childhood.

Look at Servier’s pattern over the past three years and you see a deliberate build — rare neurology and neuromuscular disease, steadily and at scale. This isn’t opportunistic gap-filling; it’s a company deciding that underserved patients represent both a moral and a commercial priority, and backing that decision with nine-figure upfront capital before confirmatory data is in hand. If you are building in rare neuromuscular disease or adjacent categories, this is what institutional conviction looks like when it writes a check.

Consider what it means that the average upfront in a US-China biotech deal has tripled in four years. According to data from Evaluate, it has risen 230% since 2022 — from $52 million to $172 million — and 2026 is already running 22% above last year’s full-year average. In the first four months of this year alone, US companies completed 19 deals with Chinese counterparts totaling $28.4 billion, six of them exceeding $1 billion.

Royalty floors are simultaneously compressing — from 7.1% to 5.5% — as Chinese biotechs trade future cash for cash now. They can afford to make that trade because the leverage has shifted. The strategic implication for anyone building in oncology, metabolic disease, or immunology is direct: the pipeline advantage that Western pharma assumed it held is now being priced as though it belongs to whoever is willing to move first.

The throughline across all three: the industry is paying up — for platforms, for patients, for pipelines — and the companies doing the paying are the ones setting the terms. For founders working at the intersection of rare disease, gene therapy, and global innovation sourcing, the market has shifted in your direction. The question now is whether you’re visible enough to be part of the conversation.